A Fluorescence-Based High-Throughput Screening Assay to Identify Growth Inhibitors of the Pathogenic Fungus Aspergillus fumigatus

  • Thomas M. SmithEmail author
  • Daryl L. Richie
  • Jianshi Tao
Part of the Methods in Molecular Biology book series (MIMB, volume 1439)


Due to the advancements in modern medicine that have resulted in an increased number of immunocompromised individuals, the incidences and the associated mortality of invasive aspergillosis have continued to rise over the past three decades despite appropriate treatment. As a result, invasive aspergillosis has emerged as a leading cause of infection-related mortality in immunocompromised individuals. Utilizing the resazurin to resorufin conversion fluorescence readout to monitor cell viability, herein, we outline a high-throughput screening method amenable to profiling a large pharmaceutical library against the clinically relevant but less frequently screened fungal pathogen Aspergillus fumigatus. This enables the user to conduct high-throughput screening using a disease-relevant fungal growth assay and identify novel antifungal chemotypes as drug leads.

Key words

Aspergillus fumigatus Fungus Antifungal Resazurin High-throughput screening (HTS) 



We would like to thank the Aspergillus fumigatus inhibitor project team including Neil Ryder, Kathryn Thompson, Roger Fujimoto, Joseph Drumm, and Dominic Hoepfner for scientific input and advice during the screen. We would like to thank Heidi Faw for safety considerations regarding Aspergillus handling. We would like to thank Alejandra Raimondi for initial assay development work. We would like to thank Melissa Grippo for compound purity testing by LC-MS.


  1. 1.
    Lin S, Schranz J, Teutsch S (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32(3):358–366CrossRefGoogle Scholar
  2. 2.
    McNeil M, Nash S, Hajjeh R, Phelan M, Conn L, Plikaytis B, Warnock D (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 33(5):641–647CrossRefGoogle Scholar
  3. 3.
    Zmeili O, Soubani A (2007) Pulmonary aspergillosis: a clinical update. QJM 100(6):317–334CrossRefGoogle Scholar
  4. 4.
    Morgan J, Wannemuehler K, Marr K, Hadley S, Kontoyiannis D, Walsh T, Fridkin S, Pappas P, Warnock D (2005) Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43(1):S49–S58CrossRefGoogle Scholar
  5. 5.
    Wilson L, Reyes C, Stolpman M, Speckman J, Allen K, Beney J (2002) The direct cost and incidence of systemic fungal infections. Value Health 5(1):26–34CrossRefGoogle Scholar
  6. 6.
    Hospenthal D, Kwon-Chung K, Bennett J (1998) Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 36(3):165–168CrossRefGoogle Scholar
  7. 7.
    Goodley J, Clayton Y, Hay R (1994) Environmental sampling for aspergilli during building construction on a hospital site. J Hosp Infect 26(1):27–35CrossRefGoogle Scholar
  8. 8.
    Brakhage J (2006) Molecular determinates of virulence in Aspegillus fumigatus. In: Heitman J (ed) Molecular principles of fungal pathogenesis. ASM Press, Washington, DCGoogle Scholar
  9. 9.
    Latgé J (1999) Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12(2):310–350Google Scholar
  10. 10.
    Herbrecht R, Denning D, Patterson T, Bennett J, Greene R, Oestmann J, Kern W, Marr K, Ribaud P, Lortholary O, Sylvester R, Rubin R, Wingard J, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar P, Hodges M, Schlamm H, Troke P, Bd P (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347(6):408–415CrossRefGoogle Scholar
  11. 11.
    Rampersad S (2012) Multiple applications of Alamar Blue as an indicator of metabolic function and cellular health in cell viability bioassays. Sensors 12(9):12347–12360CrossRefGoogle Scholar
  12. 12.
    Pesch K, Simmert U (1929) Combined assays for lactose and galactose by enzymatic reactions. Milchw Forsch 8:551Google Scholar
  13. 13.
    Stoddart M (2011) Cell viability assays: introduction. Methods Mol Biol 740:1–6CrossRefGoogle Scholar
  14. 14.
    O'Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267(17):5421–5426CrossRefGoogle Scholar
  15. 15.
    Ahmed S, Jr RG, Walsh J (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170(2):211–224CrossRefGoogle Scholar
  16. 16.
    Fai P, Grant A (2009) A rapid resazurin bioassay for assessing the toxicity of fungicides. Chemosphere 74(9):1165–1170CrossRefGoogle Scholar
  17. 17.
    Monteiro M, Mdl C, Cantizani J, Moreno C, Tormo J, Mellado E, Lucas JD, Asensio F, Valiante V, Brakhage A, Latgé J, Genilloud O, Vicente F (2012) A new approach to drug discovery: high-throughput screening of microbial natural extracts against Aspergillus fumigatus using resazurin. J Biomol Screen 17(4):542–549CrossRefGoogle Scholar
  18. 18.
    Mania D, Hilpert K, Ruden S, Fischer R, Takeshita N (2010) Screening for antifungal peptides and their modes of action in Aspergillus nidulans. Appl Environ Microbiol 76(21):7102–7108CrossRefGoogle Scholar
  19. 19.
    Yamaguchi H, Uchida K, Nagino K, Matsunaga T (2002) Usefulness of a colorimetric method for testing antifungal drug susceptibilities of Aspergillus species to voriconazole. J Infect Chemother 8(4):374–377CrossRefGoogle Scholar
  20. 20.
    Araujo R, Rodrigues A (2004) Variability of germinative potential among pathogenic species of Aspergillus. J Clin Microbiol 42(9):4335–4337CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Thomas M. Smith
    • 1
    Email author
  • Daryl L. Richie
    • 2
  • Jianshi Tao
    • 3
  1. 1.Center for Proteomic ChemistryNovartis Institutes for BioMedical Research, Inc.CambridgeUSA
  2. 2.Infectious Diseases AreaNovartis Institutes for BioMedical Research, Inc.EmeryvilleUSA
  3. 3.Genomics Institute of the Novartis Research FoundationSan DiegoUSA

Personalised recommendations